Equity Briefing : GNOM, AFFY and MRK are Notable Gainers in Healthcare
(Thomson Reuters ONE) -
Major U.S. stock indices pared most of its early losses and now trading near to
session high after ending sharply lower in yesterday's session as few Few Fed
officials thought of another round of quantitative easing. There are several
healthcare stocks which are showing notable headlines in today's session.
Affymax, Inc.(NASDAQ:AFFY) jumped sharply as its partner, Takeda
Pharmaceuticals, has reached an agreement to supply their anemia treatment
Omontys to U.S. dialysis centers run by Germany's Fresenius Medical Care.
GlaxoSmithKline plc (NYSE:GSK) stock fell 2.70% to $44.31 in the early hour
after the company today said that it has withdrawn a supplemental New Drug
Application to the U.S. Food and Drug Administration, or FDA, for Tykerb, or
lapatinib, in combination with trastuzumab for treating breast cancer.
Additionally, the company announced that data have been received from the Phase
III Harmony 8 study and from the event driven meta-analysis for assessment of
cardiovascular safety conducted across the albiglutide clinical programme.
Complete Genomics, Inc. (NASDAQ:GNOM) shares increased 1.37% to $2.97 after the
company announced that its Long Fragment Read (LFR) technology for whole genome
sequencing dramatically improves accuracy, enables fully-phased genomes, and
significantly reduces the amount of DNA required for testing. The company's LFR
technology should accelerate the use of whole genome sequencing by physicians to
diagnose and treat their patients.
Johnson & Johnson (NYSE:JNJ) stock fell 0.28% to $67.71 in the morning hour. On
July 9, 2012, Bayer AG and Johnson & Johnson's anti-blood-clotting pill Xarelto
won priority review status from the U.S. Food and Drug Administration for the
treatment of deep vein thrombosis and pulmonary embolism. The priority review
also includes the drug's use in the long-term prevention of venous
thromboembolism in patients who have already suffered an attack.
Merck & Co., Inc. (NYSE:MRK) shares climbed 4.19% to $42.94 after the company's
experimental osteoporosis drug odanacatib has shown that it reduces fracture
risk, prompting outside monitors to recommend that the study be stopped early.
The company expects to take a number of months to wind up the trial but will
continue with an extension trial to follow up on certain safety issues flagged
by the Data Monitoring Committee. The company expects to submit regulatory
applications for U.S., European and Japanese approval of odanacatib in the first
half of next year.
Hologic, Inc. (NASDAQ:HOLX) stock gained 1.76% to $18.48 after the company
announced that it has launched marketing for $750 million aggregate principal
amount of its senior notes due 2020, in a private offering expected to close
concurrently with the completion of the company's acquisition of Gen-Probe
Incorporated, which, subject to the satisfaction of certain customary closing
conditions, including obtaining the approval of Gen-Probe's stockholders, is
expected to close on or about August 1, 2012.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1626455]
Datum: 12.07.2012 - 20:43 Uhr
Sprache: Deutsch
News-ID 165005
Anzahl Zeichen: 3869
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing : GNOM, AFFY and MRK are Notable Gainers in Healthcare"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
